![Reward related ventral striatal activity and differential response to sertraline versus placebo in depressed individuals | Molecular Psychiatry Reward related ventral striatal activity and differential response to sertraline versus placebo in depressed individuals | Molecular Psychiatry](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41380-019-0490-5/MediaObjects/41380_2019_490_Fig1_HTML.png)
Reward related ventral striatal activity and differential response to sertraline versus placebo in depressed individuals | Molecular Psychiatry
![Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder | Neuropsychopharmacology Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder | Neuropsychopharmacology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41386-019-0451-3/MediaObjects/41386_2019_451_Fig1_HTML.png)
Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder | Neuropsychopharmacology
Full article: Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement
![A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia | Nature Medicine A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-020-0806-7/MediaObjects/41591_2020_806_Fig1_HTML.png)